Kisspeptin：生殖激素调控的上游把关者

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Kisspeptin?

Kisspeptin refers to a family of neuropeptides derived from the KISS1 gene, first identified in 1996 at the Pennsylvania State University College of Medicine in Hershey, Pennsylvania — hence the name "kiss" (a nod to Hershey's chocolate kisses). The full-length peptide, kisspeptin-54 (formerly called metastin), can be cleaved into shorter biologically active fragments: kisspeptin-14, kisspeptin-13, and kisspeptin-10. All forms share a common C-terminal decapeptide sequence (kisspeptin-10) that is necessary and sufficient for receptor activation.

The significance of kisspeptin in reproductive biology was discovered in 2003 when two independent research groups identified that loss-of-function mutations in the kisspeptin receptor (KISS1R, previously known as GPR54) caused hypogonadotropic hypogonadism — a failure of puberty and reproductive function. This discovery placed kisspeptin upstream of GnRH as the fundamental trigger of the reproductive hormone cascade. For a broader overview of hormonal peptides, see our guide to hormonal and reproductive peptides.

Property	Detail
Gene	KISS1 (chromosome 1q32)
Full-Length Peptide	Kisspeptin-54 (54 amino acids)
Active Fragments	Kisspeptin-54, -14, -13, -10
Receptor	KISS1R (GPR54), a Gq-coupled GPCR
Primary Expression	Arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) of hypothalamus
Key Target	GnRH neurons in the hypothalamus
Half-Life	~28 minutes (kisspeptin-54, IV); shorter for fragments
FDA Status	Not approved; investigational

Mechanism of Action

Kisspeptin acts as the primary excitatory input to GnRH neurons in the hypothalamus. When kisspeptin binds to KISS1R on GnRH neuron cell bodies and terminals, it triggers GnRH release into the portal vasculature connecting the hypothalamus to the anterior pituitary. This GnRH pulse then stimulates LH and FSH release from pituitary gonadotrophs, which in turn drive gonadal steroid production and gametogenesis.

Two distinct populations of kisspeptin neurons have been identified in the hypothalamus, each serving different reproductive functions:

• Arcuate nucleus (ARC) kisspeptin neurons: These co-express neurokinin B (NKB) and dynorphin, forming the "KNDy" neuron population. KNDy neurons are the pulse generator for GnRH secretion, with NKB providing excitatory and dynorphin providing inhibitory input to create rhythmic kisspeptin release.
• AVPV kisspeptin neurons (in rodents) / rostral periventricular area (in primates): These neurons respond to rising estrogen levels with increased kisspeptin output, mediating the preovulatory LH surge essential for ovulation. This is the positive feedback arm of the HPG axis.

Integration with Sex Steroid Feedback

Kisspeptin neurons express estrogen receptor alpha (ERα), androgen receptors, and progesterone receptors, allowing them to serve as the primary relay for sex steroid feedback to the reproductive axis. In the ARC, sex steroids inhibit kisspeptin expression (negative feedback), while in the AVPV/rostral periventricular area, estrogen stimulates kisspeptin expression (positive feedback that triggers the LH surge).

Research and Clinical Investigation

Puberty and Reproductive Development

The role of kisspeptin in puberty has been demonstrated through both human genetics and animal models. Activating mutations in KISS1 or KISS1R cause central precocious puberty, while inactivating mutations cause isolated hypogonadotropic hypogonadism with absent puberty. Kisspeptin expression in the hypothalamus increases dramatically at puberty onset, and administration of exogenous kisspeptin to prepubertal animals can advance puberty.

IVF and Assisted Reproduction

Perhaps the most clinically advanced application of kisspeptin research is in assisted reproduction. Professor Waljit Dhillo's group at Imperial College London has conducted several clinical trials exploring kisspeptin-54 as an alternative trigger for oocyte maturation in IVF cycles. Traditionally, human chorionic gonadotropin (HCG) is used for this purpose, but HCG carries a risk of ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication.

Kisspeptin triggers a more physiological cascade — stimulating endogenous GnRH, which then triggers endogenous LH release — potentially providing effective oocyte maturation with a lower risk of OHSS. Published trials have reported successful oocyte maturation and live births following kisspeptin triggering, with no cases of OHSS in high-risk patients. While promising, larger randomized controlled trials are needed to establish non-inferiority compared to standard protocols.

Hypothalamic Amenorrhea and Hypogonadism

Research has demonstrated that kisspeptin administration can restore pulsatile LH secretion in women with hypothalamic amenorrhea and in men with hypogonadotropic hypogonadism. Single-dose and short-term infusion studies have shown dose-dependent increases in LH and FSH, confirming the ability of exogenous kisspeptin to activate the HPG axis in humans.

Safety and Tolerability

In clinical trials conducted to date, kisspeptin-54 has demonstrated a favorable safety profile. The most common adverse effect is mild injection site discomfort. Because kisspeptin triggers a physiological hormone cascade rather than directly stimulating the ovaries, the theoretical risk of OHSS is lower compared to direct gonadotropin administration or HCG triggering.

However, kisspeptin research remains in relatively early clinical stages. Long-term safety data are limited, and the effects of repeated or chronic kisspeptin administration on reproductive axis sensitivity, receptor desensitization, and downstream organ function have not been fully characterized. As with all investigational agents, caution is warranted.

Regulatory Status

Kisspeptin is not FDA-approved for any indication. It remains an investigational compound with clinical trials ongoing primarily in the United Kingdom and Europe. There is no commercially available pharmaceutical formulation. Research-grade kisspeptin is available through specialized suppliers, but its use outside of clinical trials is not sanctioned by regulatory agencies. The compound represents a promising but still-developing area of reproductive medicine research.